Nd:YAG Laser Goniopuncture for Late Bleb Failure After Trabeculectomy With Adjunctive Mitomycin C

Remo Susanna Jr, MD; Carlos G. De Moraes, MD; Luciana M. Alencar, MD, PhD; Robert Ritch, MD

IMPORTANCE There is an increasing need to prolong trabeculectomy success rates with minimally invasive procedures.

OBJECTIVE To investigate the safety and efficacy of Nd:YAG laser goniopuncture (LGP) in lowering intraocular pressure (IOP) in eyes having late bleb failure following trabeculectomy with mitomycin C administration.

DESIGN, SETTING, AND PARTICIPANTS Prospective, noncomparative, interventional cohort at a referral glaucoma practice, including 19 eyes of 19 patients with uncontrolled glaucoma after failed trabeculectomy.

INTERVENTIONS All eyes had ischemic nonfunctioning blebs with patent internal ostia and underwent Nd:YAG LGP, followed by a 5-fluorouracil injection.

MAIN OUTCOMES AND MEASURES The IOP and the number of antiglaucoma medications before and after the procedure, as well as presurgical and postsurgical appearance of the blebs, using the Indiana Bleb Appearance Grading Scale classification.

RESULTS The mean (SD) time of LGP after trabeculectomy was 35.7 (32.3) months, and the mean (SD) follow-up period after LGP was 6.0 (1.1) months (range, 4.4-8.4 months). The mean (SD) IOP had decreased from 20.9 (4.5) mm Hg (range, 15.5-29.0 mm Hg) to 11.9 (4.1) mm Hg (range, 5.0-21.0 mm Hg) (P < .001). The only complications observed after LGP were 2 cases of hypotony, which resolved spontaneously. Compared with baseline Indiana Bleb Appearance Grading Scale classifications, 2 eyes showed an increase in bleb height and 10 eyes showed an increase in bleb extension. None of the eyes had a positive Seidel test result. The mean (SD) number of hypotensive agents per eye had decreased from 0.7 (1.1) to 0.3 (0.7) after the procedure. At the last follow-up visit, 15 eyes (79%) had achieved an IOP of 15 mm Hg or less, with a minimum IOP reduction of 20% from baseline without medication use.

CONCLUSIONS AND RELEVANCE The Nd:YAG LGP is a safe and effective procedure for lowering IOP in eyes with ischemic nonfunctioning blebs and patent trabeculectomy ostia. This is a promising solution to rescue failed trabeculectomies and can potentially prolong trabeculectomy success rates.
The success of trabeculectomy depends on the creation of a filtering bleb. Early and late failure is usually attributable to subconjunctival fibrosis. For late failure, surgical intervention such as needling procedures or surgical revision is usually necessary. Needling is an effective procedure to restore function of encapsulated blebs by mechanical dissection of the subconjunctival scar tissue, and a large proportion of failed or failing blebs can be rescued. With varying definitions of success, rates of 7% to 69% have been reported for needling alone and of 75% to 94% for needling with simultaneous or adjunctive administration of antifibrotic agents (5-fluorouracil or mitomycin C). Complications can occur and may be serious.

Laser goniopuncture (LGP) is most frequently associated with nonpenetrating surgery, as an attempt to augment filtration by converting it to a full-thickness procedure with rupture of the trabeculo-Descemet membrane. The procedure has the benefit of being noninvasive, fast, simple, and inexpensive. It is widely performed after deep sclerectomy, with success rates between 64% and 83%, and has a low complication rate. Numerous investigators have attempted to use the Nd:YAG laser to rescue failing filtering blebs, internally or externally, with reasonable success. However, all these studies included eyes with failed trabeculectomy due to internal ostium obstruction or conjunctival fibrosis. The objective of this study was to investigate the safety and efficacy of Nd:YAG LGP to reopen the pathway from the anterior chamber to the subconjunctival space in ischemic nonfunctioning blebs with patent internal ostia.

Methods

Patient Selection
In this prospective, noncomparative, interventional cohort, we included patients who underwent LGP at a referral glaucoma practice by a single glaucoma expert (R.S.). This study was approved by the local committee of ethics, was performed in accordance with the tenets of the Declaration of Helsinki, and complied with the Health Insurance Portability and Accountability Act regulations. Written informed consent was obtained from all participants. Patients had late elevation of intraocular pressure (IOP) after trabeculectomy performed with mitomycin C administration (defined as an IOP above individual target pressures), as well as patent internal ostia on gonioscopy and ischemic nonfunctioning blebs (V0 or V1 by the Indiana Bleb Appearance Grading Scale classification). Before and after laser surgery, IOP was measured twice using Goldmann applanation tonometry, with at least a 2-hour difference between measurements. We calculated the mean of the IOP measurements before the procedure and at the last follow-up visit for comparison purposes.

The conventional definition of complete success described in the literature to this sample was applied. It is defined as an IOP of 15 mm Hg or less, with a minimum IOP reduction of 20% from baseline at the last follow-up visit without medication use.

Results
We included 19 eyes of 19 patients, among whom 58% (11 patients) were female, while 84% (16 patients) were of white race/ethnicity and 16% (3 patients) were Asian. The mean (SD) time of LGP after trabeculectomy was 35.7 (32.3) months.

The mean (SD) IOP before laser surgery was 20.9 (4.75) mm Hg (range, 15.5-29.0 mm Hg) and had significantly decreased to 5.8 (2.9) mm Hg immediately after LGP (range, 0.0-11.0 mm Hg) (P < .001). On the day after LGP, the mean (SD) IOP was 9.3 (4.3) mm Hg (range, 2.0-17.0 mm Hg). At a mean (SD) of 6.0 (1.1) months (range, 4.4-8.4 months) after LGP, the mean (SD) IOP had decreased to 11.9 (4.1) mm Hg (range, 5.0-21.0 mm Hg) (P < .001). The mean (SD) reduction was −9.0 (6.3) mm Hg (range, −19.5 to 0.5 mm Hg), or −40.5% (24.0%) (range, −68.8% to 3.2%). The mean (SD) number of hypotensive agents per eye was 0.7 (1.1) at baseline. At the last follow-up visit, the mean (SD) number of hypotensive agents per eye was 0.3 (0.7). Medication use was not increased in any of the eyes between baseline and the last follow-up visit.

At the last follow-up visit, 15 eyes (79%) had achieved an IOP of 15 mm Hg or less, with a minimum IOP reduction of 20% from baseline without medication use (Figure 1). Compared with baseline Indiana Bleb Appearance Grading Scale classifications, 2 eyes showed an increase in bleb height, and 10 eyes showed an increase in bleb extension. None of the eyes had a positive Seidel test result. Figure 2 shows the preoperative and postoperative bleb appearance of the case shown in the Video. Despite the ischemic bleb appearance, the surrounding conjunctiva was elevated regardless of pre-existing tissue scarring.

We observed 2 cases of hypotony (IOP < 5 mm Hg) after LGP. On the first day after LGP, both eyes had IOPs of 2 mm Hg. One of the eyes showed a peripheral choroidal detachment, which resolved spontaneously within 1 week, and no eye developed...
hypotony maculopathy. At the last follow-up visit, both eyes had an IOP of 10 mm Hg.

Discussion

In some eyes with failed trabeculectomies but no visible obstruction to the internal ostium and an ischemic bleb, we have shown that LGP may break the source of increased resistance that is impairing aqueous flow from the anterior chamber to the subconjunctival space. The procedure was successful in 79% (15 of 19 eyes) of our cases at the last follow-up visit, with an average IOP reduction of 41% from baseline.

In 1977, Ticho and Ivry first reported on the use of laser surgery to break the resistance in failing trabeculectomies. They used argon laser and a gonioprism to puncture pigmented membranes over the internal ostium. Other authors obtained similar success with pigmented membranes but concluded that the procedure did not work on nonpigmented membranes. For nonpigmented membranes, Cohn et al showed that in 32% of cases the Nd:YAG laser was useful to reopen filtration fistulas, with a mean sustained IOP reduction of 9.8 mm Hg. In subsequent years, attempts were made with argon and Nd:YAG lasers and through internal or transconjunctival approaches, with varied success rates.*

Most of the above studies involved visible membranes, vitreous, iris, or debris obstructing the inner ostium. In our patients, no obstruction to the sclerectomy site was visible, and all blebs had an ischemic appearance. In addition, most of the previous studies were performed when the use of antifibrotic agents (5-fluorouracil and mitomycin C) was not standard practice in trabeculectomy. Success rates of trabeculectomy increased considerably after mitomycin C was introduced. However, complication rates associated with ischemic and avascular blebs also increased, including hypotony and scleral melting at the site of surgery. Therefore, we hypothesize that exposure to antifibrotic agents may have facilitated reopening of the ostium due to increased fragility of the sclera. In our sample, it was unclear what the exact cause of resistance was. It is possible that the laser application promoted holes in the scleral flap, which had been weakened by the use of mitomycin C.

Success rates (of varying definitions) of 7% to 69% have been reported for needling alone and of 75% to 94% for needling and laser goniopuncture (see the Video), the intraocular pressure had dropped to 10 mm Hg without medication use.

*References 12, 14, 15, 17, 18, 20, 21, 23-25.
Nd:YAG Laser Goniopuncture for Late Bleb Failure

Moraes, Alencar.

Drafting of the manuscript: Susanna, Gustavo De Moraes.

Analysis and interpretation of data: All authors.

Acquisition of data: Susanna, Gustavo De Moraes.

Study concept and design: Susanna, Gustavo De Moraes.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Gustavo De Moraes, Alencar.

Obtained funding: Ritch.

Administrative, technical, or material support: Susanna.

Study supervision: Susanna, Gustavo De Moraes.

Conflict of Interest Disclosures: None reported.

Funding/Support: The study was supported by the Edith C. Blum Foundation.

Role of the Sponsor: The Edith C. Blum Foundation had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


